Real-World Evaluation of Eko Algorithms in a Point of Care Setting
- Conditions
- Murmur, HeartPathologic MurmurAtrial FibrillationInnocent MurmursHeart Murmurs
- Registration Number
- NCT05459545
- Lead Sponsor
- Eko Devices, Inc.
- Brief Summary
The purpose of this research is to prospectively test and validate the utility of Eko artificial intelligence (AI) plus Eko Murmur Analysis Software (EMAS) murmur characterization in algorithm in a real world, point-of-care setting.
- Detailed Description
Eko has developed a platform to aid in screening for cardiac conditions using a digital stethoscope and machine-learning algorithms to detect the presence or absence of heart conditions such as heart murmurs and atrial fibrillation.
In November 2019, the US Food and Drug Administration (FDA) granted Eko a 510(k) clearance for the marketing of "Eko AI", a set of machine learning algorithms that includes atrial fibrillation (AF) and heart murmur detection. The detection of heart murmurs may aid in detecting occult and dangerous valvular heart disease (VHD). Other Eko AI outputs include bradycardia, tachycardia, noisy signal, QRS duration, and unclassified data. Eko AI has accuracy comparable to physician judgment (atrial fibrillation sensitivity of 98.9% and specificity of 96.9%, murmur sensitivity of 87.6% and specificity of 87.8%). Both AF and VHD can cause significant morbidity and mortality when missed or diagnosed late.
Eko has further developed the murmur detection function of Eko AI to now not only identify whether a murmur is present, but also to inform the clinician of its timing during the cardiac cycle (systole vs diastole), and whether it is innocent or structural. We are calling this product the Eko Murmur Analysis Software (EMAS) and submitted a premarket notification to FDA in December 2021.
This study sets out to understand the utility of the Eko AI plus EMAS murmur characterization algorithm in real world use. Collecting data in a point-of-care setting will demonstrate how accurately the algorithm characterizes murmurs in comparison to an AI-unassisted clinical examination. Algorithm output and clinical determination will be confirmed by echocardiographic ground truth, with the results being blinded until the end of the patient visit.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 371
- Patient consents to participation
- Willing to have heart sounds recorded with an electronic stethoscope
- Willing to undergo echocardiography
- Willing to undergo a 12-lead electrocardiogram
- Adults aged 65 years and older
- History of at least one of the following: hypertension, BMI β₯ 30, diabetes mellitus, hyperlipidemia, atrial fibrillation, myocardial infarction, stroke/TIA, previous coronary surgery, or previous coronary angiography
- No prior diagnosis of valve disease or heart murmur
- Patient is unwilling or unable to give written informed consent
- Patients experiencing a known or suspected acute cardiac event
- Under the age of 65 years old
- Prior diagnosis of valve disease or heart murmurs
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sensitivity and Specificity of Eko's AI relative to PCP auscultation and ground truth 02/20/2022 - 05/20/2024 Sensitivity and specificity of Eko's murmur detection algorithm relative to ground truth and PCP auscultation ground truth. Ground truth is defined as echocardiography-confirmed clinically-significant (graded "mild-to-moderate" or greater severity) VHD that is associated with a murmur, as confirmed by an expert panel.
Positive and negative predictive values for AI detecting new VHD 02/20/2022 - 05/20/2024 Positive and negative predictive values of Eko's algorithms for detecting new clinically significant valvular heart disease
Sensitivity and Specificity of Eko's AI relative to ground truth 02/20/2022 - 05/20/2024 Sensitivity and specificity of Eko's murmur detection algorithm relative to ground truth. Ground truth is defined as echocardiography-confirmed clinically-significant (graded "mild-to-moderate" or greater severity) VHD that is associated with a murmur, as confirmed by an expert panel.
Positive and negative predictive values for PCP detecting new VHD 02/20/2022 - 05/20/2024 Positive and negative predictive values of a PCP's outpatient visit for detecting new clinically significant valvular heart disease
- Secondary Outcome Measures
Name Time Method Sensitivity and Specificity of Eko's AI relative to echocardiographic ground truth. 02/20/2022 - 05/20/2024 Sensitivity and specificity of Eko's murmur detection algorithm relative to echocardiographic ground truth.
Performance of the machine algorithm vs. the physician 02/20/2022 - 05/20/2024 Performance of the machine algorithm vs. the physician
Number of cardiac tests and consultations ordered 02/20/2022 - 05/20/2024 Number of cardiac tests and consultations ordered
Trial Locations
- Locations (4)
Pentucket Medical Associates
πΊπΈLawrence, Massachusetts, United States
Maria Medical Center
πΊπΈDunn, North Carolina, United States
Edgewater Medical Center
πΊπΈLillington, North Carolina, United States
Hometown Medical PLLC
πΊπΈLillington, North Carolina, United States